One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...

While glucose-lowering therapies as a whole did not significantly reduce dementia risk, GLP-1 receptor agonists (GLP-1Ras) were linked to a 45% lower risk of dementia.

Michael W. Schwartz, MD, discusses the effectiveness of GLP1 receptor agonist drugs, such as semaglutide and tirzepatide, in ...

People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer ...

An observational study published in JAMA Oncology looks at GLP-1 receptor agonists and cancer risk in adults with obesity. Prof Paul Pharoah, Professor of Cancer Epidemiology, Cedars-Sinai Medical ...

The active ingredient in the HonXi patch is SMGT-GLP-1, a glucagon-like peptide-1 receptor agonist. This compound is known for its ability to stimulate insulin secretion, inhibit glucagon release, and ...

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ...

The analysis found that obesity-related cancer occurred in 150 of 3,178 surgery patients (5.76 cases per 1,000 person-years) and in 148 of 3,178 patients taking GLP-1s (5.64 cases per 1,000 person ...